Non-myeloablative Allogeneic Stem Cell Transplantation For Treatment Of The Mds The-raeb1 Cases And Literature Review,

Myelodysplastic syndromes (MDS) are malignant clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by a heightened potential to evolve into acute myelocytic leukemia (AML). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment. Conventional myeloablative allo-HSCT has high hematologic toxicity, the transplant-related complications increases in frequency and serverity with advancing age. With reducing the hematopoietic toxicity and intensifing immunologic treatment, non-myeloablative allogeneic hematopoietic stem cell transplantation (allo-NST) is more tolerable and is safely applicable to patients who have been previously ineligible for conventional allo-HSCT because age, organ dysfunction or other comorbidity. Increased understanding of the pathophysiology of MDS has led to the identification of new therapeutic approaches. We observe one patient with MDS-RAEB-1 who has received allo-NST and review related documents to summarize the pathophysiology, prognostic factors and the advance of treatment of MDS.